Blonanserin, a novel atypical antipsychotic agent not actively transported as substrate by P-glycoprotein.
Although blonanserin, a novel atypical antipsychotic agent with dopamine D(2)/serotonin 5-HT(2A) antagonistic properties, displays good brain distribution, the mechanism of this distribution has not been clarified. P-glycoprotein [(P-gp) or multidrug resistance protein 1 (MDR1)] is an efflux transporter expressed in the brain and plays an important role in limiting drug entry into the central nervous system (CNS). In particular, P-gp can affect the pharmacokinetics and efficacy of antipsychotics, and exacerbate or soothe their adverse effects. In this study, we conducted in vitro and in vivo experiments to determine whether blonanserin is a P-gp substrate. Risperidone and its active metabolite 9-hydroxyrisperidone, both of which are P-gp substrates, were used as reference drugs. Affinity of blonanserin, risperidone, and 9-hydroxyrisperidone for P-gp was evaluated by in vitro transcellular transport across LLC-PK1, human MDR1 cDNA-transfected LLC-PK1 (LLC-MDR1), and mouse Mdr1a cDNA-transfected LLC-PK1 (LLC-Mdr1a). In addition, pharmacokinetic parameters in the brain and plasma (B/P ratio) of test compounds were measured in mdr1a/1b knockout (KO) and wild-type (WT) mice. The results of in vitro experiments revealed that P-gp does not actively transport blonanserin as a substrate in humans or mice. In addition, blonanserin displayed comparable B/P ratios in KO and WT mice, whereas B/P ratios of risperidone and 9-hydroxyrisperidone differed markedly in these animals. Our results indicate that blonanserin is not a P-gp substrate and therefore its brain distribution is unlikely to be affected by this transporter.
Pharmacokinetics Research Laboratories, Dainippon Sumitomo Pharma, Co., Ltd., 3-1-98 Kasugadenaka, Konohana-ku, Osaka, Japan.
Tomoko
T
Inoue
Kenichi
K
Osada
Masaaki
M
Tagawa
Yuriko
Y
Ogawa
Toshiaki
T
Haga
Yoshihisa
Y
Sogame
Takanori
T
Hashizume
Takashi
T
Watanabe
Atsushi
A
Taguchi
Takashi
T
Katsumata
Masashi
M
Yabuki
Noboru
N
Yamaguchi
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000235:genetics / Q000378:metabolism*; D000818:Animals; D014150:Antipsychotic Agents / Q000097:blood / Q000493:pharmacokinetics*; D001693:Biological Transport, Active; D001921:Brain / Q000378:metabolism*; D002461:Cell Line, Transformed; D006801:Humans; D007555:Isoxazoles / Q000097:blood / Q000493:pharmacokinetics; D018374:LLC-PK1 Cells; D051379:Mice; D008815:Mice, Inbred Strains; D018345:Mice, Knockout; D000068882:Paliperidone Palmitate; D010879:Piperazines / Q000097:blood / Q000493:pharmacokinetics*; D010880:Piperidines / Q000097:blood / Q000493:pharmacokinetics*; D011743:Pyrimidines / Q000097:blood / Q000493:pharmacokinetics; D018967:Risperidone / Q000097:blood / Q000493:pharmacokinetics; D013552:Swine
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D014150:Antipsychotic Agents; D007555:Isoxazoles; D010879:Piperazines; D010880:Piperidines; D011743:Pyrimidines; C079310:blonanserin; D018967:Risperidone; D000068882:Paliperidone Palmitate